enGene Holdings Inc. (ENGN)
NASDAQ: ENGN · Real-Time Price · USD
7.51
+0.01 (0.13%)
Nov 21, 2024, 1:12 PM EST - Market open
Company Description
enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs.
Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.
The company was founded in 2023 and is based in Saint-Laurent, Canada.
enGene Holdings Inc.
| Country | Canada |
| Founded | 1999 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 33 |
| CEO | Ronald H. Cooper |
Contact Details
Address: 7171 Rue Frederick Banting Saint-Laurent, QC H4S 1Z9 Canada | |
| Phone | 514 332 4888 |
| Website | engene.com |
Stock Details
| Ticker Symbol | ENGN |
| Exchange | NASDAQ |
| Fiscal Year | November - October |
| Reporting Currency | USD |
| CIK Code | 0001980845 |
| CUSIP Number | 46429B226 |
| ISIN Number | CA29286M1059 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Ronald H. W. Cooper | Chief Executive Officer and Director |
| Dr. Alex Nichols Ph.D. | President and Chief Operating Officer |
| Dr. Anthony T. Cheung Ph.D. | Co-Founder and Chief Scientific Officer |
| John C. Brown D.Sc., FRSC, Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| David Ryan Daws | Chief Financial Officer and Head of Business Development |
| Joan Connolly | Chief Technology Officer |
| Lee G. Giguere | Chief Legal Officer and Corporate Secretary |
| Sharon Tan | Vice President of Project Management and Head of Program Management |
| Dr. Raj Pruthi M.D. | Chief Medical Officer |
| Paul Erickson | Non-Executive Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 14, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial ownership by individuals |
| Nov 13, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 13, 2024 | S-3 | Registration statement under Securities Act of 1933 |
| Nov 12, 2024 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 1, 2024 | SC 13D/A | [Amend] General statement of acquisition of beneficial ownership |
| Oct 28, 2024 | 424B3 | Prospectus |
| Oct 25, 2024 | 8-K | Current Report |
| Oct 21, 2024 | SCHEDULE 13G/A | Filing |